EGFR and cancer: However, this combination would need to effectively eliminate cancer cells before they demonstrate classical signs of resistance to EGFR inhibitors, including the de novo upregulation of EGFR signaling pathways (Section 2.4), as these would downregulate CDKis, as well as oppose CDK4/6 inhibition through the increased levels in CYCLIN D1.